SARS Associated Corona Virus (SCV)

975
Konu 114
SARS Associated Corona Virus
(SCV)
$\GÕQ06$56$VVRFLDWHG&RURQD9LUXV6&9(G&HQJL]0ÕVÕUOÕJLO$\GÕQ7ÕSYHGLúKHNLPOL÷LQGH
genel ve özel Mikrobiyoloji. Konu 114. Sa:975-*QHú\D\ÕQHYL$QNDUD
*(1(/g=(//ø./(5
%X KDVWDOÕN \ÕOÕQÕQ LNLQFL \DUÕVÕQGD X]DNGR÷X $V\D¶GD JULSDO LQIHNVL\RQ
JLEL RUWD\D oÕNPÕúWÕU 6ROXQXP \HWPH]OL÷L VHEHEL\OH |OPOH VRQXoODQDQ YDND VD\ÕVÕ
KHU JHoHQ D\JLGHUHNDUWPÕúWÕU%XKDVWDOÕ÷DVHUWDNXWVROXQXPVHQGURPXDQODPÕQD
JHOHQ6HYHUH$FXWH5HVSLUDWRU\6\QGURPH6$56LVPLYHULOPLúWLU
&'& YH 'Q\D VD÷OÕN |UJWQH LON UDSRUODU dLQ +RQJ .RQJ .DQDGD
øQGRQH]\D)LOLSLQOHU6LQJDSXU7D\ODQGYH9LHWQDP¶GDQJHOPLúWLU\ÕOÕúXEDWÕQGD
KDVWDOÕN WDP RODUDN WDQÕPODQDELOPLúWLU 'DKD VRQUD øQJLOWHUH 6ORYHQ\D $PHULND
$OPDQ\D¶GDQYDNDUDSRUODUÕJHOPLúWLU-Nisan-¶WHONHGHWHVSLWHGLOPLúNHQ0D\ÕV-WDULKLQHNDGDUWRSODPONHGHQYDNDUDSRUODUÕELOGLULOPLúWLU
HastalDUÕQ oR÷X - \Dú DUDVÕQGDGÕU \DúÕQ DOWÕQGD VDGHFH ELUNDo YDND
YDUGÕU +DVWDODU DUDVÕQGD FLQVL\HW D\ÕUÕPÕ WHVSLW HGLOHPHPLúWLU %XQD UD÷PHQ HUNHN
KDVWDODUÕQRUDQÕFLYDUÕQGDGÕU
(7.(1ø
(OGHNL ELOJLOHUH J|UH 6$56 KDVWDOÕ÷ÕQÕQ HWNHQL NRURQDYLUXV 7RU VXúXGXU %X
virusa SARS-DVVRFLDWHG&RURQD9LUXV6&9LVPLYHULOPLúWLU'L÷HUNRURQDYLUXVODUJLEL
80-QPE\NO÷QGHSOHRPRUILNVIHULNYH\DHOLSVúHNOLQGHKHOLNDOVLPHWULGHGLU
<]H\LQGHNL oÕNÕQWÕODU SHSORPHU QP JHQLúOL÷LQGH QP X]XQOX÷XQGDGÕU 7HN
VDUPDO51$VÕYDUGÕUdHYUHVLQGH-QPNDOÕQOÕ÷ÕQGDOLSLWELU]DUÕEXOXQXU6&9µQX
izole edip Macaca fascicularis PD\PXQODUÕQD KDVWDOÕ÷Õ EXODúWÕUPDN PPNQ
ROPXúWXU
Bu virusun 29751-ED]oLIWOLNJHQRPXQXQVHNDQVÕWHVSLWHGLOPLúWLUWDQe ORF
2SHQ5HDGLQJ)UDPHXFXEXOXQPDNWDGÕU%XUDGDQDQODúÕOGÕ÷ÕQDJ|UHL\LELOLQHQKHU
iki koronavirus genomuna (HCoV-OC43 ve HCoV-229E) orta seviyede bir benzerlik
göstermektedir (300 nükleotitten %50-NDGDUÕEHQ]HPHNWHGLU
6$56 KDVWDVÕQÕQ VROXQXP VÕYÕODUÕQGDQ KXPDQ PHWDSQHXPRYLUXV L]ROH
HGLOPLúWLU %X GXUXPGD PHWDSQHXPRYLUXV¶XQ ELU NR-LQIHNW|U P ROGX÷X YH\D 6$56
KDVWDOÕ÷ÕQÕQ EX LNL YLUXVXQ ELUOLNWHOL÷L LOH PL PH\GDQD oÕNWÕ÷Õ \ROXQGD GH÷LúLN J|UúOHU
YDUGÕU
SINIFLANDIRMASI:
$VOÕQGD Coronaviridae IDPLO\DVÕQGD \HU DODQ YLUXVODUÕQ E\N oR÷XQOX÷X
VDGHFH KD\YDQGD KDVWDOÕN \DSDU %XQODUÕQ LoHULVLQGH LQVDQGD VROXQXP \ROX
KDVWDOÕ÷ÕQDVHEHSRODQ+XPDQUHVSLUDWRU\&RURQD9LUXV+&9µXQUKLQRYLUXVODUJLEL
VW VROXQXP \ROXQGD KDVWDOÕN \DSDELOGL÷L |QFHGHQ ELOLQL\RUGX \ÕOÕQGD 7\UHO YH
%\QRHD\UÕFD\ÕOÕQGD+DPUHYH3URFNQRZEXYLUXVXVR÷XNDOJÕQOÕ÷ÕEHOLUWLOHUL
RODQ LQVDQÕQ QD]RIDULQJHDO \ÕNDPD VX\XQGDQ L]ROH HGHUHN J|QOO LQVDQODUD
X\JXODPÕú YH EX LQVDQODUGD VR÷XN DOJÕQOÕ÷ÕQD EHQ]HU ELU KDVWDOÕN ROXúWXUPD\Õ
EDúDUPÕúODUGÕ%XYLUXVODUDVÕUDVÕ\OD%YH(LVPLQLYHUPLúOHUGL¶GHWDQH
976
GDKD NRURQDYLUXV WHVSLW HGLOPLúWLU <HQL EXOXQDQODUÕQ oR÷X VÕoDQGD YH NXúODUGD
SQ|PRQL\DSDELOGL÷LLoLQYH|OGUFROPDGÕ÷ÕLoLQ]HULQGH\HWHULQFHGXUXOPDPÕúWÕ
6&9LVHPXKWHPHOHQEXYLUXVODUGDQELUWDQHVLQLQVSRQWDQPXWDV\RQJHoLUPLú
ELU IRUPXGXU %L\RORMLN VDYDú DPDFÕ\OD JHQHWLN PKHQGLVOHUL WDUDIÕQGDQ \DUDWÕOGÕ÷ÕQD
GDLUV|\OHQWLOHUGHYDUGÕU
$17ø-(1<$3,6,h5(7ø/0(6ø
SCV viryonun kapsitindeki M(pro) antijeni, konak dokuda replikasyon
IDDOL\HWOHULQL \|QHWHQ ELU SURWHLQD]GÕU GL÷HU LVPL &/SUR GXU 9LUXVXQ D\UÕFD
KHPDJOWLQLQOHUL YDUGÕU%XKHPDJOWLQLQOHU0\[RYLUXVODUGDROGX÷XJLELHULWURVLWOHUGHQ
NHQGLOL÷LQGHQD\UÕOPD]ODU
Transmissible gastroenteritis virus (TGEV)’un M(pro) antijeni ile SCV’un
0SURDQWLMHQLDUDVÕQGDPROHNOHUELUEHQ]HUOLNYDUGÕU%XVHEHSOH7*(9LQIHNVL\RQX
geçirenlerin anti-6&9DQWLNRUXWDúÕPDODUÕPPNQGU
&RURQDYLULGDH IDPLO\DVÕQGDNL YLUXVODU IDUNOÕ DQWLMHQLN JXUXED D\UÕOÕUODU g]JO
RODUDN 6&9¶XQ KDQJL DQWLMHQLN JXUXS LoHULVLQH \HUOHúWLULOHFH÷L KHQ] NHVLQOLN
ND]DQPDPÕúWÕUDPDKHUELUJXUXSLoLQGH\HUDODQNRURQDYLUXVODUGL÷HUJXUXEXQ\HOHUL
LOH oDUSUD] UHDNVL\RQ YHUHELOPHNWHGLU %X |]HOOLN NRURQDYLUXV WHúKLV NLWOerinin SCV
WDQÕVÕQGDNXOODQÕOPDVÕNROD\OÕ÷ÕQÕJHWLULU
Koronaviruslar, insan embriyonu trekae organ kültüründe, bebek fare
EH\QLQGHWHNWDEDNDOÕGRNXNOWUOHULQGHUHWLOHELOLU6&9LoLQHQX\JXQYDVDW9HUR(
hücre kültürüdür.
'ø5(1d/ø/ø.
dHYUH NRúXOODUÕQD GLUHQFL RUWDPÕQ QHP PLNWDUÕQD YHVÕFDNOÕ÷ÕQDED÷OÕGÕU.XUX
RUWDPGD ]DPDQOD LQIHNWLYLWHVLQL ND\EHGHU 6R÷XNWD YH YFXW VDOJÕODUÕQÕQ LoHULVLQGH
daha uzun süre infektif kalabilir.
6&9¶QXQ OLSLW ]DUIÕ EXOXQPDVÕ VHEHEL\OH DONRO YH HWHU JLEL OLSLW o|]Fülere
IHYNDODGHGX\DUOÕGÕU
$QWLVHSWLNOHUH GX\DUOÕGÕU $QWLWEHUNOR DQWLVHSWLNOHU YH KLSR LOH NÕVD VUHGH
LQKLEH ROXU 'URSOHWOHU KDOLQGH KDYD\D NDUÕúWÕ÷ÕQGD DQWLVHSWLN X\JXODPDVÕ VSUH\
úHNOLQGH ROPDOÕGÕU 'XYDU ]HPLQ YH NRQWDPLQH PDWHU\DO KLSR YH\D DONollü antiseptik
solüsyonlar ile silinmelidir.
<$37,ö,+$67$/,./$5
øQVDQGD YH PD\PXQGD 6$56 KDVWDOÕ÷Õ \DSWÕ÷Õ ELOLQPHNWHGLU $\QÕ DLOHGHNL
GL÷HU YLUXVODUD EHQ]HU RODUDN KD\YDQGD SQ|PRQL HWNHQL ROPDVÕ GD PXKWHPHOGLU
+DVWDOÕN ED]Õ LQVDQODUGD VXENOLQLN VH\UHWPHNWHGLU %D]Õ LQVDQODUGD LVH |OGUF
RODELOPHNWHGLU %D÷ÕúÕNOÕN EÕUDNÕS EÕUDNPDGÕ÷Õ KHQ] LQFHOHQPHPLúWLU 'X\DUOÕ
ELUH\OHUGH ELOKDVVD GL\DEHWLNOHUGH SURJQR]XQ D÷ÕU VH\UHWPHVL PPNQGU %WQ
YDNDODU D\QÕ VHUWOLNWH VH\UHWPH] $NFL÷HU EHOLUWLVL ELOH YHUPHGHQ L\LOHúHQ YDNDODU
YDUGÕU
.URQLNOHúWL÷LUDSRUHGLOPHPLúWLU3RUW|UONUDSRUHGLOPHPLúWLU
%(/ø57ø/(5ø
øQNEDV\RQ SHU\RGX - JQGU DPD JQH NDGDU X]D\DELOLU øQNEDV\RQ
peryodu uzun olan vakalar daha hafif seyreder.
5DVWODQPDVÕNOÕ÷ÕQDJ|UHLONNOLQLNEHOLUWLOHUL\NVHNDWHú!ƒ&KX]XUVX]OXN
KLVVL WLWUHPH ER÷D] \DQPDVÕ |NVUN NDV D÷UÕVÕ EDú D÷UÕVÕ ELODWHUDO SQ|PRQL
VROXQXPXQ GHULQOL÷LQLQ NÕVDOPDVÕ YH\D ]RU QHIHV DOPD úHNOLQGHGLU $OÕúÕODJHOPLú
VROXQXP\ROXKDVWDOÕ÷ÕQDEHQ]HUEHlirtiler verir.
'|NQW UHQDO JDVWURLQWHVWLQDO YH Q|URORMLN EXOJXVX \RNWXU %D]Õ YDNDODUGD
\NVHNDWHúG|QHPLQGHGL\DUHUDSRUHGLOPLúWLU
977
+DVWDODUÕQ -¶QGH LON EHOLUWL DWHúWLU VLQGH úPH YH WLWUHPH
%49-¶ÕQGDNDVD÷UÕVÕ-69’unda öksürüktür, %42 sinde ise ilk belirti dispnedir.
9DNDODUÕQ DQFDN - NDGDUÕQGD KDVWDOÕ÷ÕQ J|UOPHVLQGHQ -7 gün sonra
DOW VROXQXP \ROODUÕ ROD\D NDWÕOÕU gNVUN NXUX YH VHUWWLU GLVSQH JHQHOOLNOH VRQUDGDQ
RUWD\D oÕNDU (QWEDV\RQ YH\D YHQWLODV\RQ FLKD]Õ LOH VROXQXPD \DUGÕP HGLOPHVL
JHUHNHELOLU%XQDUD÷PHQYDNDODUÕQVDGHFH-NDGDUÕKLSRNVLVROXQXPNROODSVÕYH
|OPLOHVRQXoODQDELOLU'LDEHWOLKDVWDODUGD6$56VHEHEL\OH|OPRUDQÕWXU
+DVWDOÕN DWLSLN EHOLUWLOHU GH YHUHELOLU gUQH÷LQ GLVHPLQH LQWravasküler
NRDJORSDWL EHOLUWLVL YHUHQ ELU KDVWDQÕQ DNFL÷HU U|QWJHQOHULQGH ELU GH÷LúLNOLN
J|UOPHPLú DPD NRPSWHUL]H WRPRJUDIL &7 LOH DNFL÷HUGH NRQVROLGH RGDNODU WHVSLW
HGLOPLú YH VROXQXP VDOJÕVÕQGD 6&9 J|VWHULOPLúWLU 7LSLN 6$56 NOLQL÷L VRQUDGDQ
JHOLúPLúWLU
(UNHQG|QHPGHDNFL÷HUU|QWJHQOHULQRUPDOJ|UQWYHULUøOHUOH\HQG|QHPOHUGH
oHNLOHQ DNFL÷HU U|QWJHQOHULQGH IRNDO LQWHUVWLV\DO LQILOWUDWODUD ED÷OÕ NRQVROLGH VDKDODU
hemen daima tespit edilir.
TANI:
(Q VDGÕN WDQÕ \|QWHPL DNFL÷HULQ UDG\RORMLN RODUDN LQFHOHQPHVLGLU 6DOJÕQ
E|OJHVLQGHNL 6$56 úSKHOL YDNDODUGD U|QWJHQ YH NDQ EXOJXODUÕ WHúKLV LoLQ \HWHUOLGLU
+DVWDOÕ÷ÕQ HUNHQ G|QHPLQGH YH\D LON GHID RUWD\D oÕNWÕ÷ÕQGD VROXQXP VDOJÕODUÕQGD
HOHNWURQPLNURVNRSLOHYLUVQYDUOÕ÷ÕQÕJ|VWHUPHNYH\DNOWUGHretmek gerekebilir.
Koronaviruslara özgül immünolojik testler SCV için de uygulanabilir.
Radyolojik testler:
$NFL÷HU URQWJHQLQGH NRQVROLGDV\RQ DUDQPDOÕGÕU $NFL÷HU SHUNV\RQGD
GROJXQGXU RVNOWDV\RQ LSXFX YHUPH\HELOLU %LU oDOÕúPDGD U|QWJHQ EHOLUWLVL YHren 23
KDVWD KHQ] U|QWJHQ EHOLUWLVL YHUPH\HQ 6$56 KDVWDVÕ YH U|QWJHQ EHOLUWLVL
YHUPH\HQ WDQH 6$56 úSKHOL KDVWDQÕQ DNFL÷HUL RSDVLWH YH NRQVROLGDV\RQ
DoÕVÕQGDQ &7 LOHLQFHOHQPLú6$56KDVWDOÕ÷ÕQÕQU|QWJHQEHOLUWLVLYHUPHGHQ|QFH&7
LOHWHúKLVHGLOHELOHFH÷LJ|UOPúWU7RSODPWDQHHWNLOHQHQDNFL÷HUVHJPHQWLQGHQ
WDQHVL DNFL÷HULQ DOW OREXGXU +HSVLQGH RUWDN EXOJX RSDVLILNDV\RQ JURXQG-glass
opacification), konsolidasyon, interlobuler septalarda ve interstisyal fragmanlarda
NDOÕQODúPDGÕU 5|QWJHQ EHOLUWLVL YHUPHGHQ |QFH EX OH]\RQODUÕQ VD\ÕVÕ YH oDSÕ
NoNWUDNFL÷HULQSHULIHULQGH\HUOHúLUOHU5|QWJHQGHEHOLUWLYHUHQOH]\RQODUJHQHOOLNOH
DNFL÷HULQKHPPHUNH]LQGHKHPGHSHULIHULQGHRODELOLUOHUDPDVDQWUDOOH]\RQODUKHPHQ
KHUYDNDGDVD\ÕFDD]GÕU
øPPQRORMLNWHVWOHU
6ROXQXP VDOJÕODUÕQGD JXUXS , NRURQDYLUXV SROLNORQDO DQWLNRUODUÕQ IORUHVDQ
ER\DODUOD J|VWHULOPHVL WDQÕ\D \DUGÕP HGHU 6ROXQXP VDOJÕODUÕQÕQ 9HUR ( KFUH
kültürüne inokülasyonu ile virusun gösterilmesi veya serolojik olarak koronaviruslara
|]JONRURQDYLUXVUHYHUVWUDQVNULSWD]ODUÕLOH\DSÕODQ3&5WHVWOHULWDQÕ\ÕGR÷UXODU
Transmisyon elektron mikroskopunda standart boyama prosedürü ile lobut
úHNOLQGHNLSHSORPHUOHULL]OHQHELOLU
Hematolojik testler:
Erken dönemde lökopeni yoktur veya a]GÕUDPDOHQIRVLWVD\ÕVÕD]DOPÕúRODUDN
EXOXQXU+DVWDODUÕQ¶LQGHODFWDWHGHK\GURJHQDVH!8/¶LQGHNUHDWLQ
fosfokinaz yükselebilir (>3,000 IU/L), hepatik transaminazlar normalin 2- NDWÕQD
kadar yükselebilir.
+DVWDODUÕQVLQGHLONYHRUtak laboratuvar bulgusu lactate dehydrogenase
\NVHOPHVLGLU¶ÕQGDKLSRNDOVHPL-¶VÕQGDOHQIRSHQLVLQGHUKLQRUUKHD
GÕU
978
øOHUOH\HQG|QHPGHKDVWDODUÕQ-VLQGHWURPERVLWRSHQLYDUGÕU-150,000/µL).
$\ÕUGHGLFLWDQÕ
Balgam ve kaQ ER\DQDUDN YH NOWU \DSÕODUDN EDNWHUL\HO SQ|PRQL HOLPLQH
edilmelidir. Atipik pnömoni etkenleri (Mycoplasma pneumoniae, Chlamydia
pneumoniae, Legionella pneumophilaDUDQPDOÕYHHOLPLQHHGLOPHOLGLU,QIOXHQ]D$%
YHVROXQXPVLQVLW\DOYLUXVKDVWDOÕNODUÕQGDQD\UÕOPDVÕJHUHNOLGLU
7('$9ø
+DVWD NDUDQWLQD\D DOÕQPDOÕGÕU +DVWDQÕQ \DNÕQ WHPDVWD EXOXQGX÷X \DNÕQODUÕ
X\DUÕOPDOÕYHHQD]ELUKDIWDER\XQFDDNFL÷HUEHOLUWLOHULL]OHQPHOLGLU
%X JQN ELOJLOHULPL]H J|UH EX KDVWDOÕN DQWLEL\RWLNULEDYLULQNRUWLNRVWHUoid
oOV LOH WHGDYL HGLOPHNWHGLU $WLSLN EDNWHUL\HO SQ|PRQLGH NXOODQÕODQ ELU DQWLEL\RWLN
verilmesinin sebebi konservatiftir. Mesela beta laktam veya bir makrolit seçilebilir.
0DNVLPXPHIHNWLIGR]KDVWDQÕQNLORVXQDX\JXQELoLPGHD\DUODQÕU
Ribavirin iseNRURQDYLUXVODU]HULQHHWNLOLRODQDQWLYLUDOLODoWÕU5LEDYLULQ¶LQGR]X
JQGH GHID J GÕU 5LEDYLULQ X\JXODQDQ 6$56¶OÕ KDVWDODUÕQ ¶VÕQGD KHPROL]
J|UOPHNWH¶XQGDKHPRJORELQVHYL\HVLJG/¶QLQDOWÕQDGúPHNWHGLU$PDKDOD
en uygun tedavidir. RLEDYLULQNRQWUHQGLNHROGX÷XQGD2VHOWDPLYLUYHULOHELOLU
.RUWLNRVWHURLGOHU RUDO YH\D SDUHQWHUDO \ROGDQ YHULOHELOLU 7HUFLKDQ øQWUDYHQ|]
PHWK\OSUHGQLVRORQHPJYHULOLUYHKDVWDQÕQVROXQXPXJ|]OHPDOWÕQGDWXWXOXU
Antibiyotik, ribavirin ve methylprednisoORQH LOH WHGDYL HGLOHQ6$56úSKHOL
YDNDGD WDQHVL KÕ]OD YH NDOÕFÕ RODUDN G]HOPLú KDVWD GDKD \DYDú RODUDN
G]HOPLú KDVWDODUGDQ VDGHFH WDQHVLQH QRQLQYD]LI YHQWLODV\RQ RNVLMHQ PDVNHVL
X\JXODPDNJHUHNOLROPXúHQWEDV\RQJHUHNPHPLú|OPJ|UOPHPLúWLU
5LQRYLUXV&SURLQKLELW|UOHULQL6&9¶XQ0SURDQWLMHQLQLKHGHIDODFDNúHNLOGH
PRGLIL\HHGHUHN\HQLWHGDYLPHWRWODUÕDUDQPDNWDGÕU
(3ø'(0ø<2/2-ø
+DVWDOÕ÷ÕQ ONHOHU DUDVÕ \D\ÕOPDVÕQGD VH\DKDW HGHQLQVDQODUÕQYHKD\YDQODUÕQ
UROYDUGÕU.XOXoNDVUHVLQLQ\DNODúÕNELUKDIWDNDGDUROPDVÕVHEHEL\OHELUKDIWDGDQ
GDKD X]XQ VUHQ GHQL]DúÕUÕ \ROFXOXNODUGD JHPL LOH VH\DKDW HGHQOHULQ KDVWDOÕ÷Õ
EHOLUWLOHUL RUWD\D oÕNPDGDQ WDúÕPDVÕ NoN ELU LKWLPDOGLU +DOEXNL PLNURRUJDQL]PD LOH
infekte olan ama henüz hLoELUEHOLUWLYHUPH\HQELULQVDQÕQXoDNLOHVH\DKDWHGHUHNELU
EDúND ONH\H JLUPHVL SHN PPNQGU %|\OH ELU KDVWD KDYDDODQÕQGD PXD\HQH
HGLOHUHN RUWD\D oÕNDUÕODPD] =DWHQ XOXVODUDUDVÕ KDYD\ROODUÕ OLPDQODU NDUJR
PHUNH]OHUL NRQWURO DOWÕQGD WXWXOPDVÕQD UD÷men 7-Mart-2003’te Toronto ‘da birisi 144
NLúLOLNGL÷HULNLúL\LYHVD÷OÕNoDOÕúDQÕQÕHWNLOH\HQLNLVDOJÕQUDSRUHGLOPLúWLU
2-Nisan-WDULKLQGHEXKDVWDOÕNWDQNLúL|OPúYHPXKWHPHOHQNLúL
KDVWDODQPÕúWÕU (VHU \D\ÕQD KD]ÕUODQGÕ÷Õ VÕUDGD 0D\ÕV WDULKL LWDEDUÕ LOH EX
KDVWDOÕNWDQ NLúL |OPú PXKWHPHOHQ NLúL KDVWDODQPÕúWÕU %X UDNDPODU
KDVWDOÕ÷ÕQLOHUOHPHKÕ]ÕQÕJ|VWHUPHNWHGLU
hONHPL]GHKHQ]KLo6$56YDNDVÕELOGLULOPHPLúWLU
&'& úSKHOL YDNDODUÕQ UDSRU HGLOPHVL LoLQ ELU Lnternet adresi ve bir telefon
ELOGLUPLúWLUhttp://www.cdc.gov/ncidod/sars , 770-488-7100).
%8/$ù0$-KORUNMA:
%XODúPD\DNÕQWHPDVLOHROXU
9LUXVXQGURSOHWOHULOHoHYUH\HVDoÕOGÕ÷ÕELOLQPHNWHGLU6ROXQXPVDOJÕODUÕQGDYH
ELOKDVVD DWHúOL G|QHPGH GÕúNÕGD 6&9 WHVSLW HGLOPLúWLU 'ROD\ÕVÕ\ODKDVWDQÕQEWQ
oÕNDUWÕODUÕLQIHNWLINDEXOHGLOPHOLGLU2UWDNNXOODQÕPDUDoODUÕ\DWDN\DVWÕNNDúÕNKDYOX
JL\VLOHU ELU VUH YLUXV EXOXQGXUDELOLUOHU +DVWDQÕQ NXOODQÕP Hú\DODUÕ NRQWDPLQH
979
PDWHU\DO RODUDN NDEXO HGLOPHOLGLU <DNÕQ WHPDVWD EXOXQPDN |SúPHN D\QÕ Hú\DODUÕ
NXOODQPDN GXUXPXQGD EXODúPD PPNQGU 6&9 GURSOHWOHU KDOLQGH KDYD\D VDoÕOÕU
YH\DYFXWVDOJÕODUÕLOHHú\DODUDEXODúDELOLU'URSOHWOHULQVROXQPDVÕJ|]EXUXQD÷Õ]
PXNR]DVÕQDWHPDVHWPHVLLQIHNVL\RQXEXODúWÕUDELOLU
+DVWDQÕQ PO EDOJDPÕQGD PLO\RQ YLUDO 51$ WHVSLW HGLOPLúWLU +DOEXNL
YLUXVKDVWDQÕQVHUXPGDoRNGDKDD]PLNWDUGDEXOXQXU
Hastalar daima 1) eldiven, 2)koruyucu önlük ve 3)maske ile muayene
HGLOPHOLGLUHOOHULQ\ÕNDQPDVÕELOKDVVD|QHPOLGLU0DVNHJ|]OHULGHLoHULVLQHDODFDN
úHNLOGHROPDOÕGÕU0DVNHQLQNRUX\XFXHWNLVLGL÷HUEWQ|QOHPOHUGHQID]ODGÕU
6$56 KDVWDOÕ÷ÕQD \DNDODQDQ KDVWDKDQH SHUVRQHOL ]HULQGH JHUL\H G|QN
incelemelerde bu G|UW|QOHPGHQHQD]ELULVLQLDOPDGÕ÷ÕWHVSLWHGLOPLúWLU%X|QOHPOHUL
DODQ KDVWDKDQH SHUVRQHOLQGH KDVWDOÕ÷D UDVWODQPDPÕúWÕU 0DVNHQLQ NRUX\XFXOX÷X
S |]HO |QO÷Q NRUX\XFXOX÷XQGDQ S YH HO \ÕNDPDQÕQ
NRUX\XFXOX÷XQGDQ S ID]ODGÕU øQIHNWH RODQODUÕQ KHSVLQLQ HQ D] ELU GHID
PDVNHVLQLoÕNDUWWÕNODUÕWHVSLWHGLOPLúWLUS 8QXWPDPDN JHUHNLUNL YDNDODUÕQ |QHPOL ELU NÕVPÕ KDVWDKDQHOHUGHQ
EXODúPDúHNOLQGHROPDNWDGÕU+DVWDKDQH|QFHVLQGHEXODúPDGDKDD]GÕU%XVHEHSOH
VD÷OÕN SHUVRQHOLQLQ |QFH NHQGLVLQL VRQUD EDúNDODUÕQÕ NRUXPDN LoLQ GURSOHWOHU LOH
PFDGHOHHWPHVLúDUWWÕU
+HQ]ELUDúÕVÕ\RNWXU
KAYNAKLAR:
1. $NDQ (URO &RURQDYLUXVODU *HQHO YH g]HO 9LURORML QF EDVNÕ ø]PLU 6DUD\ 7ÕS .LWDEHYL
1994: 495-502.
2. Anand K, Ziebuhr J, Wadhwani P, et al., Coronavirus Main Proteinase (3CLpro) Structure:
Basis for Design of Anti-SARS Drugs. Science, 2003; May 13 (in press).
3. Booth CM, Matukas LM, Tomlinson GA, et al.,Clinical Features and Short-term Outcomes of
144 Patients With SARS in the Greater Toronto Area. JAMA, 2003; May 6 (in press).
4. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with
severe acute respiratory syndrome. N Engl J Med, 2003; 348(20):1967-1976.
5. Fouchier RA, Kuiken T, Schutten M, et al. Aetiology: Koch's postulates fulfilled for SARS
virus. Nature, 2003; 423(6937):240.
6. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe
acute respiratory syndrome. N Engl J Med, 2003; 348(20):1953-1966.
7. Lapinsky SE, Hawryluck L. ICU management of severe acute respiratory syndrome.
Intensive Care Med, 2003; May 9 (in press).
8. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong
Kong. N Engl J Med, 2003; 348(20):1986-1994.
9. Rickerts V, Wolf T, Rottmann C, et al.Clinical presentation and management of the severe
acute respiratory syndrome (SARS). Dtsch Med Wochenschr, 2003; 128(20):1109-1114.
10. Marra MA, Jones SJ, Astell CR, et al. The Genome Sequence of the SARS-Associated
Coronavirus. Science, 2003; May 1 (in press).
11. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute
respiratory syndrome. Lancet 2003;361(9366):1319-25.
12. Seto WH, Tsang D, Yung R, et al. Effectiveness of precautions against droplets and
contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS).
Lancet, 2003; 361(9368):1519-1520.
13. So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe
acute respiratory syndrome. Lancet, 2003; 361(9369):1615-1617.
14. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome
in Hong Kong. N Engl J Med, 2003; 348(20):1977-1985.
15. Wong KT, Antonio GE, Hui DS, et al. Thin-Section CT of Severe Acute Respiratory
Syndrome: Evaluation of 74 Patients Exposed to or with the Disease. Radiology, 2003; May 8 (in
press).